Medical oncology capabilities in practice (CiPs) – mapping to 2017 curriculum competencies

<table>
<thead>
<tr>
<th>Oncology Capabilities in practice (CiPs)</th>
<th>Mapping to 2017 curriculum competencies</th>
</tr>
</thead>
</table>
| 7. Applying knowledge and understanding of the scientific principles that underpin malignancy for the provision of high-quality and safe patient-centred cancer care | Section 1.3 Planning diagnostic, prognostic investigations and interpretation of clinical data 1.4 Germline and tumour genomics  
Section 1.5 Planning therapeutic intervention  
Section 1.10 Surveillance, screening and survivorship  
Section 4: Scientific Basis of Malignancy  
Section 5.1 Therapeutics and safe prescribing  
Section 6.2 Paraneoplastic syndromes, complications of disease and comorbidity  
Section 7: Supportive therapies and palliative care                                                                 |
| 8. Delivering the acute oncology take, managing oncological emergencies and providing oncology advice to other healthcare professionals as part of an Acute Oncology Service and managing the AOS team | Section 1: Professional skills  
Section 2 Medical Leadership and Management  
Section 6: Acute Oncology  
Section 7: Supportive therapies and palliative care                                                                                                                                                                                    |
| 9. Providing continuity of care to oncology in-patients to include the effective management of disease and treatment-related complications, the acutely deteriorating patient and the palliative care/end-of-life needs of those with advanced cancer | Section 1 Professional skills  
Section 3.2: Ethical issues in Oncology  
Section 3.4: Legal framework  
Section 6 : Acute Oncology  
Section 5: Therapeutics and safe prescribing  
Section 7: Supportive therapies and palliative Care  
Section 8: Training in Site-specific Tumour types                                                                                                                  |
| 10. Working effectively within and contributing expert opinion to the tumour site-specific multi-disciplinary team (MDT) meeting to inform evidence-based management plans individualised to the needs of each patient, leading discussions where appropriate | Section 2: Medical Leadership and Management  
Section 4: Scientific basis of malignancy  
Section 8: Training in Site-specific Tumour types                                                                                                                                                                                  |
| 11. Assessing patients at all stages of the cancer pathway from diagnosis to end-of-life care, considering the holistic needs of individuals and the additional needs of vulnerable groups to formulate patient-centred management plans | Section 1 : Professional Skills  
Section 5: Systemic Anti-cancer therapies  
Section 6: Acute Oncology  
Section 7 : Supportive therapies and Palliative Care  
Section 8 : Training in site-specific tumour types                                                                                                                                                                                   |
| 12. Safely and effectively delivering, and managing patients receiving, standard systemic anticancer therapies (SACT) in | Section 4.2: Pharmacology of anticancer therapies and drugs used in symptom control  
Section 5: Systemic Anti-cancer therapies                                                                                                                                                                                                 |
<table>
<thead>
<tr>
<th><strong>Oncology Capabilities in practice (CiPs)</strong></th>
<th><strong>Mapping to 2017 curriculum competencies</strong></th>
</tr>
</thead>
</table>
| the curative, neo-adjuvant, adjuvant and palliative settings | Section 6: Acute Oncology  
Section 8: Training in site-specific tumour types |
| 13. Acting as an advocate for health promotion and high-quality cancer survivorship, advising on cancer prevention, management of long-term treatment-related sequelae and patient self-management strategies | Section 1.10: Surveillance, screening and survivorship  
Section 2: Medical Leadership and Management  
Section 3.2: Ethical Issues in oncology  
Section 3.4: Legal framework  
Section 8: Training in site-specific tumour types |
| **Medical Oncology CiPs** | **Mapping to 2017 curriculum competencies** |
| 14. Safely and effectively deliver, and manage patients receiving, intensive complex systemic anti-cancer therapies | Section 1: Professional skills  
Section 3: Clinical research, ethics and economics  
Section 4.2: Pharmacology of anticancer therapies and drugs used in symptom control  
Section 5: Systemic Anti-cancer therapies  
Section 6: Acute Oncology  
Section 7: Supportive therapies and palliative care  
Section 8: Training in site-specific tumour types-intensive therapies |
| 15. Developing guidelines and protocols to safely implement diagnostic and systemic anticancer therapeutic (SACT) approaches | Section 2: Medical Leadership and Management  
Section 3.3: Provision of cancer services and resource management  
Section 5: Systemic anti-cancer therapies |
| 16. Managing the training and supervision of non-medical prescribers of systemic anticancer therapies | Section 2.9: Teaching and training  
Section 3.3: Provision of cancer services and resource management  
Section 5: Systemic Anti-cancer therapies |
| 17. Integrating biomarkers and genomic information to refine diagnosis and develop personalized treatment plans for cancer patients | Section 1.3: Planning diagnostic, prognostic investigations and interpretation of clinical data  
Section 1.4: Germline and tumour genomics  
Section 1.5: Planning therapeutic intervention  
Section 4: Scientific Basis of malignancy |
| 18. Implement clinical trials of systemic anticancer treatments at investigator level for all phases, with the skills to lead late phase (Phase III) trials as Principal Investigator | Section 2: Medical leadership and management  
Section 3: Clinical research, Ethics and Economics  
Section 4: Scientific basis of malignancy |